carteolol has been researched along with Disease Models, Animal in 4 studies
Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 5.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| "Oxprenolol and carteolol were observed to have mild effects on the abnormal ECG as compared with propranolol." | 5.27 | [The abnormal ECG and the appearance of methacholine-induced arrhythmias in SART mice and effects of beta-blockers, oxprenolol, propranolol, and carteolol]. ( Harada, N; Hata, T; Itoh, E; Kita, T, 1984) |
| "Carteolol treatment increased beta-adrenergic receptor density, and the high carteolol dose restored SR Ca2+-ATPase and myofibrillar ATPase activities, along with creatine kinase, lactate dehydrogenase, aspartate transaminase, and ATP synthase activities, to normal." | 1.30 | Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. ( Bristow, MR; DiSalvo, TG; Gwathmey, JK; Hajjar, RJ; Khan, F; Kim, CS; Matsumori, A, 1999) |
| "Oxprenolol and carteolol were observed to have mild effects on the abnormal ECG as compared with propranolol." | 1.27 | [The abnormal ECG and the appearance of methacholine-induced arrhythmias in SART mice and effects of beta-blockers, oxprenolol, propranolol, and carteolol]. ( Harada, N; Hata, T; Itoh, E; Kita, T, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zammataro, A | 1 |
| Saletti, R | 1 |
| Civiale, C | 1 |
| Muccilli, V | 1 |
| Cunsolo, V | 1 |
| Foti, S | 1 |
| Hata, T | 1 |
| Kita, T | 1 |
| Itoh, E | 1 |
| Harada, N | 1 |
| Gwathmey, JK | 2 |
| Kim, CS | 1 |
| Hajjar, RJ | 2 |
| Khan, F | 1 |
| DiSalvo, TG | 1 |
| Matsumori, A | 1 |
| Bristow, MR | 1 |
| Washington, B | 1 |
| Butler, K | 1 |
| Doye, AA | 1 |
| Jang, M | 1 |
4 other studies available for carteolol and Disease Models, Animal
| Article | Year |
|---|---|
Simultaneous quantification of carteolol and dorzolamide in rabbit aqueous humor and ciliary body by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry.
Topics: Animals; Antihypertensive Agents; Aqueous Humor; Carteolol; Chromatography, High Pressure Liquid; Ci | 2010 |
[The abnormal ECG and the appearance of methacholine-induced arrhythmias in SART mice and effects of beta-blockers, oxprenolol, propranolol, and carteolol].
Topics: Animals; Arrhythmias, Cardiac; Autonomic Nervous System Diseases; Carteolol; Disease Models, Animal; | 1984 |
Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol.
Topics: Adenosine Triphosphate; Adenylyl Cyclases; Adrenergic beta-Antagonists; Animals; Blood Pressure; Bod | 1999 |
Heart function challenged with beta-receptor agonism or antagonism in a heart failure model.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Blood Pressure; Ca | 2001 |